Women who took raloxifene were less likely to develop invasive estrogen-receptor (ER) positive breast cancer compared with women who did not, according to data from a randomized controlled trial published online June 10 in the Journal of the National Cancer Institute. The drug did not reduce the risk of non-invasive cancer or invasive ER-negative cancers.
More...